Plozasiran achieved statistically significant median reductions in triglycerides up to 80% and mean reductions in APOC3 up to 94% at month 10
- Plozasiran achieved a statistically significant reduction in incidence of acute pancreatitis versus placebo
- Plozasiran is the company’s first investigational RNAi-based therapy to show clinical efficacy in a Phase 3 study
- Arrowhead plans to highlight recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event as part of the 2024 Summer Series of R&D Webinars
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.